Plunkett Research Online: Cardio3 Biosciences

CARDIO3 BIOSCIENCES (CLYYF:GREY) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Celyad SA is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has .....



Cardio3 Biosciences
Ticker: CLYYF
Exchange: GREY
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 32 10394100
Fax: 32 10394141
Address: Rue Edouard Belin 2
Mont-Saint-Guibert, 1435 Belgium

Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
ContactsDescription
Christian HomsyCEO/Director
Patrick JeanmartCFO
See More
Celyad SA is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has .....See More See More

Auditor: BDO Bedrijfsrevisoren - BDO Reviseurs d'Entreprises
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: